Nothing said here yet.
to join the conversation.
| Kelly Jason RSee remarks | Sell | 45,682 | $463.4K | Mon, Oct 19 |
| Shetty Reshma P.See remarks | Sell | 22,369 | $226.9K | Mon, Oct 19 |
| Canton Barry | Sell | 22,369 | $226.9K | Mon, Oct 19 |
| Shetty Reshma P.See remarks | Sell | 18,803 | $190.7K | Mon, Oct 19 |
| Canton Barry | Sell | 18,803 | $190.7K | Mon, Oct 19 |
| Coen Steven P.See remarks | Sell | 766 | $7.8K | Mon, Oct 19 |
| Coen Steven P.See remarks | Sell | 2,403 | $36.0K | Mon, Oct 5 |
| HENRY CHRISTIAN ODirector | Sell | 5,000 | $35.4K | Tue, Sep 15 |
| Coen Steven P.See remarks | Sell | 330 | $2.3K | Mon, Aug 24 |
Ginkgo Bioworks Holdings, Inc. (DNA) closed at $12.74 in the latest trading session, marking a -4.35% move from the prior day.
Ginkgo Bioworks has just agreed to open its Boston autonomous lab to National Science Foundation X-Labs teams, while also wiring Araceli’s high-speed imaging gear into its Nebula setup.
VANCOUVER, BC, Oct. 21, 2026 /PRNewswire/ -- Mapmygenome announced the completion of its acquisition of Vancouver-based dnaPower Inc., a pioneer in personal genomics.
The study evaluates patients with liver cancer at high risk of recurrence following surgical resection Julie Rosenberg, MD, appointed to leadership team as Chief Medical Officer PHILADELPHIA, Oct.
Following the acquisition of Catalog's assets and the appointment of Laurent Guengant as CEO earlier this year, Biomemory opened Early Access to DNA shield, its first commercial product for sovereign data protection, establishing the company as an early…
The latest analyst update on Ginkgo Bioworks Holdings includes a higher fair value estimate of US$8 and at least one price target set at US$11, which points to a reassessment of what investors might be willing to pay for the stock.
In the most recent trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $11.53, indicating a -1.96% shift from the previous trading day.
GREAT NECK, N.Y., Oct. 13, 2026 /PRNewswire/ -- Google Trends data indicate that relative search interest for 'PDRN' in the U.S. increased 650% over the one-year period analyzed.